Insulin degludec: A novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 1, 2012, Pages 9-14

  Meneghini, Luigi F ^a   Miranda Palma, Bresta ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

A1C; basal insulin; fasting plasma glucose; hypoglycemia; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; NEUTRAL INSULIN;

ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 82955205736     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.86     Document Type: Article

References (14)

1. Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24, 1936-1940 (2001).
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31, 596-615 (2008).
3. Jonassen I, Havelund S, Ribel U et al. Insulin degludec: multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulin. Diabetologia 53(Suppl. 1), S388 (2010).
4. Kurtzhals P, Heise T, Strauss HM et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24-28 June 2011.
5. Nishimura E, Sørensen AR Hansen BF et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologia 53(Suppl. 1), S388 (2010).
6. Heise T, Hövelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24-28 June 2011.
7. Heise T, Hermanski L, Nosek L et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia 53(Suppl. 1), S387 (2010).
8. Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H. Ultra-long acting insulin degludec has a flat and stable glucose-lowering effect. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24-28 June 2011.
9. Riddle MC. The treat-to-target trial and related studies. Endocr. Pract. 12(Suppl. 1), 71-79 (2006).
10. Birkeland KI, Home PD, Wendisch U et al. Insulin degludec in Type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34, 661-665 (2011).
11. Zinman B, Fulcher G, Rao PV et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with Type 2 diabetes: a 16-week, randomised, open-label, Phase 2 trial. Lancet 377, 924-931 (2011).
12. Heller S, Francisco AMO, Pei H, Russell-Jones D. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in Type 1 diabetes. Diabetes 60(Suppl. ), A19 (2011).
13. Garber AJ, King AB, Francisco AMO, Endahl L, Hollander PA. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with Type 2 diabetes. Diabetes 60(Suppl. 1), A20 (2011).
14. Meneghini L, Atkin SL, Bain S et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with Type 2 diabetes. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24-28 June 2011.